within Pharmacolibrary.Drugs.ATC.C;

model C01CA07
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 3.9999999999999996e-05,
    adminDuration  = 600,
    adminMass      = 2.5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0006,
    k12             = 1.1,
    k21             = 1.1
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C01CA07</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dobutamine is a synthetic catecholamine and direct-acting inotropic agent primarily used in the short-term treatment of cardiac decompensation due to depressed contractility resulting from organic heart disease or cardiac surgical procedures. It acts mainly through stimulation of beta-1 adrenergic receptors. Dobutamine is approved for use in acute heart failure and is administered intravenously in clinical settings.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers receiving short-term intravenous infusion.</p><h4>References</h4><ol><li><p>Lehtonen, LA, et al., &amp; Pentikäinen, PJ (2004). Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. <i>Clinical pharmacokinetics</i> 43(3) 187–203. DOI:<a href=\"https://doi.org/10.2165/00003088-200443030-00003\">10.2165/00003088-200443030-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/14871156/\">https://pubmed.ncbi.nlm.nih.gov/14871156</a></p></li><li><p>Habib, DM, et al., &amp; Minegar, C (1992). Dobutamine pharmacokinetics and pharmacodynamics in pediatric intensive care patients. <i>Critical care medicine</i> 20(5) 601–608. DOI:<a href=\"https://doi.org/10.1097/00003246-199205000-00010\">10.1097/00003246-199205000-00010</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1572184/\">https://pubmed.ncbi.nlm.nih.gov/1572184</a></p></li><li><p>Kates, RE, &amp; Leier, CV (1978). Dobutamine pharmacokinetics in severe heart failure. <i>Clinical pharmacology and therapeutics</i> 24(5) 537–541. DOI:<a href=\"https://doi.org/10.1002/cpt1978245537\">10.1002/cpt1978245537</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/699477/\">https://pubmed.ncbi.nlm.nih.gov/699477</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C01CA07;
